A. Majumdar, J. McCrea, D. Panebianco
Aug 1, 2003
Citations
10
Influential Citations
97
Citations
Quality indicators
Journal
Clinical Pharmacology & Therapeutics
Abstract
Aprepitant is a neurokinin1 receptor antagonist that enhances prevention of chemotherapy‐induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5‐hydroxytryptamine3 (5‐HT3) antagonist. Because aprepitant may be used with a variety of chemotherapeutic agents and ancillary support drugs, which may be substrates of cytochrome P450 (CYP) 3A4, assessment of the potential of this drug to inhibit CYP3A4 activity in vivo is important. The effect of aprepitant on in vivo CYP3A4 activity in humans with oral midazolam used as a sensitive probe of CYP3A4 activity was evaluated in this study.